NCT06545162View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of a Single or Multiple Ascending Doses of CPX101

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

September 20, 2025

Study Completion Date

December 20, 2025

Conditions
Overweight and Obesity
Interventions
BIOLOGICAL

CPX101 or placebo 80mg single dose

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 120mg single dose

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 160mg single dose

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 80mg Q2W

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 120mg Q2W

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 160mg Q2W

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 200mg Q2W

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 200mg single dose

CPX101 or placebo 200mg single dose

Trial Locations (3)

100000

RECRUITING

Beijing Friendship Hospital, Beijing

RECRUITING

Beijing hospital, Beijing

RECRUITING

Beijing Luhe hospital, Beijing

All Listed Sponsors
lead

Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.

INDUSTRY